Anti-phospholipid antibody syndrome

Jose F. Roldan, Robin L. Brey

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Scopus citations


The anti-phospholipid syndrome (APS) was first described in 1983. The major clinical features consist of arterial (Antiphospholipid Antibodies in Stroke Study [APASS] Group, 1990; Cervera et al., 2002; Nojima et al., 1997; Rosove and Brewer, 1992) and venous (Wahl et al., 1998) thrombosis leading to tissue ischemia and placental thrombosis resulting in recurrent fetal loss (Levy et al., 1998; Rand et al., 1997), and thrombocytopenia in the presence of anti-phospholipid antibodies (Hughes, 1983). The research definition for APS has evolved over the years to its current state including moderate to highly positive anti-cardiolipin and anti-beta-2-glycoprotein 1 (anti-b2GP-I) antibodies present twice at least 12 weeks apart and evidence for a thrombotic event or recurrent fetal loss (Miyakis et al., 2006) (Table 38.1).

Original languageEnglish (US)
Title of host publicationUncommon Causes of Stroke, 2nd Edition
PublisherCambridge University Press
Number of pages12
ISBN (Electronic)9780511544897
ISBN (Print)9780521874373
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Anti-phospholipid antibody syndrome'. Together they form a unique fingerprint.

Cite this